Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Abstract 3039: Evaluation of intra-tumoral pks+ E. coli, enterotoxigenic B. fragilis and Fusobacterium nucleatum, overall and in early onset disease, in colorectal cancer cases
Hullar, Meredith A.J. , Curtis, Keith R. , Harrison, Tabitha A. , Steinfelder, Robert S. , Berndt, Sonja I. , Figueiredo, Jane C. , French, Amy J. , Melaku, Johannes, Ugai, Tomotaka, Qu, Chenxu, Thibodeau, Steven, Zaidi, Syed Hassan Ejaz , Phipps, Amanda I. , Peters, Ulrike , investigators, on behalf of GECCO and CCFR, Harrison, Tabitha A , Lin, Yi , Buchanan, Daniel D. , Chan, Andrew T. , Drew, David A., Jenkins, Mark A. , Moreno, Vı́ctor , Ugai, Tomotaka , Ogino, Shuji , Qu, Conghui , investigators, on behalf of GECCO and CCFR

Mayo Clinic

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 3039-3039

10.1158/1538-7445.am2023-3039 Get It

Abstract Background: Colorectal cancer (CRC) incidence has increased in those 50 years or younger compared to older individuals in recent decades. While the intra-tumoral microbiome is a potent facilitator of tumorigenesis, the role of the microbiome in early onset (eo)CRC is unclear. Identification of the intra-tumoral microbiome may enhance prediction of adverse outcomes to improve survival of CRC overall age groups and eoCRC. Methods: We performed targeted sequencing of tumor and matched normal DNA samples from 3695 colorectal cancer cases within the Genetics and Colorectal Cancer Consortium (GECCO) and the Colon Cancer Family Registry (CCFR). Tumor DNA was extracted from formalin fixed paraffin embedded (FFPE) or fresh frozen tissue. Normal tissue DNA was extracted from blood or normal surrounding colorectal tissue. We designed probes for the bacterial pathogens enterotoxigenic Bacteroides fragilis (ETBF), polyketide synthase positive E. coli (pks+ EC), and Fusobacterium nucleatum (Fn). We used logistic regression to assess tumor-associated bacteria and clinical parameters, tumor molecular characteristics, and tumor stage adjusted for age, sex, and study and a Cox promotional hazard to assess association with CRC-specific survival, overall and in eoCRC, adjusted for age at diagnosis, sex, mutational burden, and microsatellite instability (MSI) and stratified baseline hazards by study. Survival data were available for 2357 and 308 patients, overall and in eoCRC, respectively. Results: The prevalence of different bacteria in tumors differed slightly overall vs. in eoCRC tumors: ETBF (5.2%, 6.3%), pks+ EC (12.9%, 14.8%), and Fn (10.4%, 8.2%). Overall, men had a lower probability of tumors with Fn (odds ratio (OR)=0.8, 95% confidence interval (CI)=0.64-0.99, p=0.04) but higher odds of tumors with pks+ EC (OR=1.38, CI=1.14-1.68, p=0.001), compared to women. The odds of prevalent Fn were higher for proximal vs distal tumors (OR=1.76, CI=1.38-2.26, p<0.001), but there was no association between tumor site and pks+ EC or ETBF. MSI-high tumors were more likely to carry Fn (OR=2.79, CI=2.08-3.75, p<0.001) and less likely to carry pks+ EC (OR=0.63, CI=0.44-0.88, p=0.008) when compared to patients with MSS tumors. In patients with non-hypermutated tumors, we observed that pks+ EC positive tumors were associated with better CRC-specific survival (HR=0.73, CI=0.57-0.93, p=0.01), whereas ETBF positive tumors (HR=1.99, CI=1,18-3.36,p=0.009) and Fn positive tumors (HR=1.33, CI=1.04-1.72, p=0.03) were associated with poorer survival. In eo-CRC patients, Fn positive status was associated with poorer survival (HR=2.4, CI= 1.056 - 5.492, p=0.026). Conclusions: We showed that the intra-tumoral microbiome differs in distribution across patient populations and patient survival over all age groups and, specifically, in eoCRC. Citation Format: Meredith A. Hullar, Keith R. Curtis, Tabitha Harrison, Yi Lin, Robert Steinfelder, Sonja I. Berndt, Daniel D. Buchanan, Andrew T. Chan, David A. Drew, Jane Figueiredo, Amy J. French, Tabitha A. Harrison, Mark A. Jenkins, Johannes Melaku, Victor Moreno, Tomotaka Ugai, Shuji Ogino, Conghui Qu, Chenxu Qu, Steven Thibodeau, Syed Zaidi, Amanda I. Phipps, Ulrike Peters, on behalf of GECCO and CCFR investigators. Evaluation of intra-tumoral pks+ E. coli, enterotoxigenic B. fragilis and Fusobacterium nucleatum, overall and in early onset disease, in colorectal cancer cases [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3039.
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , DeCamp, Malcolm M., Dilling, Thomas J. , Dowell, Jonathan E. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Grotz, Travis E. , Hegde, Aparna , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 4, 2023 | Volume: 21 | Issue: 4 | Pages: 340-350

10.6004/jnccn.2023.0020 | PMID 37015337 Get It

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options for eligible patients with resectable NSCLC.
QIM23-138: Using the Electronic Health Record (EHR) to Capture Structured Oncology Data in Real-Time at the Point-of-Care: A Mayo Clinic Comprehensive Cancer Center (MCCCC) Pilot Study
Tevaarwerk, Amye J., Harlos, Elizabeth S., VanBebber, Heather L., Misel, Eli J., Nelson, Sacha A., Stockham, Abigail L. , Haddad, Tufia C. , Mandrekar, Sumithra J. , Maurer, Matthew J. , Vanbebber, Heather, Holton, Sara J., Alberts, Steven R. , McWilliams, Robert R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2023 | Volume: 21 | Issue: 3.5 | Pages: QIM23-138

10.6004/jnccn.2022.7188 Get It

Treatment outcomes of extraskeletal Ewing sarcoma
Houdek, Matthew T. , Heidenreich, Mark J. , Ahmed, Safia K. , Petersen, Ivy A. , Rose, Peter S. , Allen-Rhoades, Wendy, Houdek, Matthew T , Allen‐Rhoades, Wendy , Siontis, Brittany L. , Robinson, Steven I.

Mayo Clinic

Journal of Surgical Oncology | March 31, 2023 | Volume: 128 | Issue: 1 | Pages: 105-110

10.1002/jso.27250 | PMID 36999583 Get It

AbstractPurposeExtraskeletal Ewing sarcoma (EES), is a rare soft tissue sarcoma. Treatment for EES commonly involves chemotherapy and surgical resection (ST) or less commonly combined chemotherapy, surgery, and radiotherapy (ST + RT). The purpose of the current study was to evaluate our institutional experience treating EES.MethodsWe reviewed 36 (18 males:18 females) patients (mean age 30 years) with a nonretroperitoneal/visceral EES treated with either ST (n = 24, 67%) or ST + RT (n = 12, 33%). All patients were treated with chemotherapy, most commonly vincristine, doxorubicin, cyclophosphamide/ifosfamide and etoposide (VDC/IE, n = 23, 66%) Radiotherapy was mostly delivered preoperatively (n = 9). The mean follow‐up was 8 years.ResultsThe 10‐year disease specific survival for patients was 78%, with no difference in the survival between patients in the ST versus the ST + RT groups (83% vs. 71%, p = 0.86). There was no difference in the 10‐year local recurrence (91% vs. 100%, p = 0.29) or metastatic free survival (87% vs. 75%, p = 0.45) between the ST and ST + RT groups.ConclusionThe results of the current study highlight the ability to achieve excellent local control with chemotherapy and surgery for EES. We recommend for multidisciplinary management of patients with EES, including chemotherapy and surgery, with use of radiotherapy if there is concern for a potentially close margin of resection.
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma
Heater, Natalie Knox , Okuno, Scott H. , Attia, Steven , Seetharam, ­Mahesh , Yoon, Janet, Chawla, Sant P. , Milhem, Mohammed , Monga, Varun , Skubitz, Keith M. , Charlson, John A. , Hirbe, Angela C. , Weiss, Mia C. , Tine, Brian A. Van , Agulnik, Mark , Robinson, Steven, Monga, Varun , Skubitz, Keith , Hirbe, Angela C , Van Tine, Brian A , Agulnik, Mark , Milhem, Mohammed M , Robinson, Steven I. , Siontis, Brittany L.

Mayo Clinic

Journal of Clinical Medicine | March 29, 2023 | Volume: 12 | Issue: 7 | Pages: 2561

10.3390/jcm12072561 | PMID 37048645 Get It

The treatment of sarcoma necessitates a collaborative approach, given its rarity and complex management. At a single institution, multidisciplinary teams of specialists determine and execute treatment plans involving surgical, radiation, and medical management. Treatment guidelines for systemic therapies in advanced or nonresectable soft tissue sarcoma have advanced in recent years as new immunotherapies and targeted therapies become available. Collaboration between institutions is necessary to facilitate accrual to clinical trials. Here, we describe the success of the Midwest Sarcoma Trials Partnership (MWSTP) in creating a network encompassing large academic centers and local community sites. We propose a new model utilizing online platforms to expand the reach of clinical expertise for the treatment of advanced soft tissue sarcoma.
Clinical Outcomes of Stereotactic Radiosurgery-Related Radiation Necrosis in Patients with Intracranial Metastasis from Melanoma
Thomson, Holly M, Ensign, Shannon P. Fortin , Edmonds, Victoria S. , Butterfield, Richard , Ashman, Jonathan B. , Zimmerman, Richard S. , Bryce, Alan H. , Vora, Sujay A., Porter, Alyx B. , Ensign, Shannon P. Fortin , Schild, Steven E. , Bryce, Alan H , Sharma, Akanksha , Patel, Naresh P. , Sio, Terence T.

Mayo Clinic

Clinical Medicine Insights: Oncology | March 21, 2023 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/11795549231161878 | PMID 36968334 Get It

Background: Radiation necrosis (RN) is a clinically relevant complication of stereotactic radiosurgery (SRS) for intracranial metastasis (ICM) treatments. Radiation necrosis development is variable following SRS. It remains unclear if risk factors for and clinical outcomes following RN may be different for melanoma patients. We reviewed patients with ICM from metastatic melanoma to understand the potential impact of RN in this patient population. Methods: Patients who received SRS for ICM from melanoma at Mayo Clinic Arizona between 2013 and 2018 were retrospectively reviewed. Data collected included demographics, tumor characteristics, radiation parameters, prior surgical and systemic treatments, and patient outcomes. Radiation necrosis was diagnosed by clinical evaluation including brain magnetic resonance imaging (MRI) and, in some cases, tissue evaluation. Results: Radiation necrosis was diagnosed in 7 (27%) of 26 patients at 1.6 to 38 months following initial SRS. Almost 92% of all patients received systemic therapy and 35% had surgical resection prior to SRS. Patients with RN trended toward having larger ICM and a prior history of surgical resection, although statistical significance was not reached. Among patients with resection, those who developed RN had a longer period between surgery and SRS start (mean 44 vs 33 days). Clinical improvement following treatment for RN was noted in 2 (29%) patients. Conclusions: Radiation necrosis is relatively common following SRS for treatment of ICM from metastatic melanoma and clinical outcomes are poor. Further studies aimed at mitigating RN development and identifying novel approaches for treatment are warranted.
Carbodiimide-Derivatized Synovial Fluid for Tendon Graft Coating Improves Long-Term Functional Outcomes of Flexor Tendon Reconstruction
Reisdorf, Ramona L., Liu, Haoyu , Bi, Chun, Vrieze, Alyssa, Moran, Steven L. , Amadio, Peter C. , Zhao, Chunfeng

Mayo Clinic

Plastic & Reconstructive Surgery | March 13, 2023 | Volume: 152 | Issue: 5 | Pages: 840e-849e

10.1097/prs.0000000000010390 | PMID 36912937 Get It

Background: Flexor digitorum profundus (FDP) tendon injury is common in hand trauma, and flexor tendon reconstruction is one of the most challenging procedures in hand surgery because of severe adhesion that exceeds 25% and hinders hand function. The surface properties of a graft from extrasynovial tendons are inferior to those of the native intrasynovial FDP tendons, which has been reported as one of the major causations. Improved surface gliding ability of the extrasynovial graft is needed. Thus, this study used carbodiimide-derivatized synovial fluid and gelatin (cd-SF-gel) to modify the surface of the graft, thus improving functional outcomes using a dog in vivo model. Methods: Forty FDP tendons from the second and fifth digits of 20 adult women underwent reconstruction with a peroneus longus (PL) autograft after creation of a tendon repair failure model for 6 weeks. Graft tendons were either coated with cd-SF-gel (n = 20) or not. Animals were euthanized 24 weeks after reconstruction, and digits were collected after the animals were euthanized for biomechanical and histologic analyses. Results: Adhesion score (cd-SF-gel, 3.15 ± 1.53; control, 5 ± 1.26; P < 0.00017), normalized work of flexion (cd-SF-gel, 0.47 ± 0.28 N-mm/degree; control, 1.4 ± 1.45 N-mm/degree; P < 0.014), and distal interphalangeal joint motion (cd-SF-gel, 17.63 ± 6.77 degrees; control, 7.07 ± 12.99 degrees; P < 0.0015) in treated grafts all showed significant differences compared with nontreated grafts. However, there was no significant difference in repair conjunction strength between the two groups. Conclusion: Autograft tendon surface modification with cd-SF-gel improves tendon gliding ability, reduces adhesion formation, and enhances digit function without interfering with graft-host healing. Clinical Relevance Statement: The authors demonstrate a clinically relevant and translational technology by using the patient’s own synovial fluid to “synovialize” an autologous extrasynovial tendon graft to improve functional outcomes following flexor tendon reconstruction.
Enhancing Functional Recovery after Segmental Nerve Defect Using Nerve Allograft Treated with Plasma-Derived Exosome
Wang, Yicun , Huang, Tony Chieh‐Ting , Li, Jialun , Long, Zeling , Reisdorf, Ramona L., Amadio, Peter C. , Zhao, Chunfeng , Moran, Steven L. , Shi, Guidong , Shin, Alexander Y. , Behfar, Atta

Mayo Clinic

Plastic & Reconstructive Surgery | March 13, 2023 | Volume: 152 | Issue: 6 | Pages: 1247-1258

10.1097/prs.0000000000010389 | PMID 36912739 Get It

Background: Nerve injuries can result in detrimental functional outcomes. Currently, autologous nerve graft offers the best outcome for segmental peripheral nerve injury. Allografts are alternatives, but do not have comparable results. This study evaluated whether plasma-derived exosome can improve nerve regeneration and functional recovery when combined with decellularized nerve allografts. Methods: The effect of exosomes on Schwann cell proliferation and migration were evaluated. A rat model of sciatic nerve repair was used to evaluate the effect on nerve regeneration and functional recovery. A fibrin sealant was used as the scaffold for exosome. Eighty-four Lewis rats were divided into autograft, allograft, and allograft with exosome groups. Gene expression of nerve regeneration factors was analyzed on postoperative day 7. At 12 and 16 weeks, rats were subjected to maximum isometric tetanic force and compound muscle action potential. Nerve specimens were then analyzed by means of histology and immunohistochemistry. Results: Exosomes were readily taken up by Schwann cells that resulted in improved Schwann cell viability and migration. The treated allograft group had functional recovery (compound muscle action potential, isometric tetanic force) comparable to that of the autograft group. Similar results were observed in gene expression analysis of nerve regenerating factors. Histologic analysis showed no statistically significant differences between treated allograft and autograft groups in terms of axonal density, fascicular area, and myelin sheath thickness. Conclusions: Plasma-derived exosome treatment of decellularized nerve allograft may provide comparable clinical outcomes to that of an autograft. This can be a promising strategy in the future as an alternative for segmental peripheral nerve repair. Clinical Relevance Statement: Off-the-shelf exosomes may improve recovery in nerve allografts.
Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design
Petersen, Ivy A. , Imai, Reiko , Hug, Eugen B., Fiore, Maria Rosaria , Fossati, Piero , Yamada, Shigeru , Orlandi, Ester , Zhang, Qing, Bao, Cihang , Seidensaal, Katharina , May, Byron C. , Harrell, Anna , Houdek, Matthew T. , Vallow, Laura A., Rose, Peter S. , Haddock, Michael G. , Ashman, Jonathan B. , Goulding, Krista , Attia, Steven , Krishnan, Sunil , Mahajan, Anita , Foote, Robert L. , Keole, Sameer R., Beltran, Chris , Welch, Eric M., Wilke, Benjamin K. , Imai, Reiko , Yamada, Shigeru , Zhang, Qing , May, Byron C , Harrell, Anna C , Houdek, Matthew T , Goulding, Krista A., Krishnan, Sunil , Foote, Robert , Karim, Mohammed, Ahmed, Safia K. , Beltran, Chris J , Hoppe, Bradford S. , DeWees, T.A. , Debus, Jürgen , Laack, Nadia N. , Karim, Mohammed

Mayo Clinic

Cancers | March 8, 2023 | Volume: 15 | Issue: 6 | Pages: 1660

10.3390/cancers15061660 | PMID 36980545 Get It

Surgical treatment of pelvic sarcoma involving the bone is the standard of care but is associated with several sequelae and reduced functional quality of life (QOL). Treatment with photon and proton radiotherapy is associated with relapse. Carbon ion radiotherapy (CIRT) may reduce both relapse rates and treatment sequelae. The PROSPER study is a tricontinental, nonrandomized, prospective, three-arm, pragmatic trial evaluating treatments of pelvic sarcoma involving the bone. Patients aged at least 15 years are eligible for inclusion. Participants must have an Eastern Cooperative Oncology Group Performance Status score of two or less, newly diagnosed disease, and histopathologic confirmation of pelvic chordoma, chondrosarcoma, osteosarcoma, Ewing sarcoma with bone involvement, rhabdomyosarcoma (RMS) with bone involvement, or non-RMS soft tissue sarcoma with bone involvement. Treatment arms include (1) CIRT (n = 30) delivered in Europe and Asia, (2) surgical treatment with or without adjuvant radiotherapy (n = 30), and (3) proton therapy (n = 30). Arms two and three will be conducted at Mayo Clinic campuses in Arizona, Florida, and Minnesota. The primary end point is to compare the 1-year change in functional QOL between CIRT and surgical treatment. Additional comparisons among the three arms will be made between treatment sequelae, local control, and other QOL measures.
Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)
Kemppainen, Jennifer L., Vitek, Carolyn R. Rohrer , Whalen, Denise A., Kolbert, Kayla J., Sikkink, Kaitlin J. , Kroc, Sarah A., Kruisselbrink, Teresa , Shupe, Gabrielle F., Knudson, Alyssa K., Burke, Elizabeth , Loftus, Elle C., Bandel, Lorelei A. , Prochnow, Carri A., Mulvihill, Lindsay A., Thomas, Brittany C. , Gamble, Dale M., Graddy, Courtney B., Garzon, Giovanna G. Moreno, Ekpoh, Idara U., Porquera, Eva M. Carmona, Hogan, Marie C. , Ters, Mireille El , Davis, III John M., Vella, Adrian, Kumar, Seema , Creo, Ana L. , Lteif, Aida, Pittock, Siobhán T. , Tebben, Peter J. , Abate, Ejigayehu G., Joshi, Avni Y. , Ristagno, Elizabeth H. , Patnaik, Mrinal S., Sabrowsky, Sonia M., Wierenga, Klaas J. , Keddis, Mira T. , Samadder, N. Jewel , Presutti, R. John , Stephens, Michael C., Roberts, Lewis R. , Faubion, William A. , Driscoll, Sherilyn W. , Selcen, Duygu , Jackson, Lauren , Ortega, Victor E. , Anderson, Sarah , Aoudia, Stacy L., Klee, Eric W. , McAllister, Tammy M., Carmona, Eva M. , Carmona, Eva M , Roberts, Lewis R , Presutti, Richard J , Tebben, Peter , Hogan, Marie C , Vairo, Filippo Pinto e , Burke, Elizabeth M., Fervenza, Fernando C. , Warrington, Kenneth J. , Koster, Matthew J. , Orandi, Amir B. , Basiaga, Matthew L. , Patnaik, Mrinal S., Schimmenti, Lisa A. , Dhamija, Radhika , Robinson, Steven I. , Wong‐Kisiel, Lily C. , Flanagan, Eoin P. , Ramanan, Vijay K. , Mauermann, Michelle L. , Lazaridis, Konstantinos N.

Mayo Clinic

No container title available | March 7, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2617916/v1 Get It

Abstract Background In the United States, rare disease (RD) is defined as a condition that affects fewer than 200,000 individuals. Collectively, RD affects an estimated 30 million Americans. A significant portion of RD has an underlying genetic cause; however, this may go undiagnosed. To better serve these patients, the Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD) was created under the auspices of the Center for Individualized Medicine (CIM) aiming to integrate genomics into subspecialty practice including targeted genetic testing, research, and education. Methods Patients were identified by subspecialty healthcare providers from 11 clinical divisions/departments. Targeted multi-gene panels or custom exome/genome-based panels were utilized. To support the goals of PRaUD, a new clinical service model, the Genetic Testing and Counseling (GTAC) unit, was established to improve access and increase efficiency for genetic test facilitation. The GTAC unit includes genetic counselors, genetic counseling assistants, genetic nurses, and a medical geneticist. Patients receive abbreviated point-of-care genetic counseling and testing through a partnership with subspecialty providers. Results Implementation of PRaUD began in 2018 and GTAC unit launched in 2020 to support program expansion. Currently, 29 RD clinical indications are included in 11 specialty divisions/departments with over 142 referring providers. To date, 1,152 patients have been evaluated with an overall solve rate of 14.1% and as high as 66.7% depending on the phenotype. Noteworthy, 42.7% of the solved or likely solved patients underwent changes in medical management and outcome based on genetic test results. Conclusion Implementation of PRaUD and GTAC have enabled subspecialty practices advance expertise in RD where genetic counselors have not historically been embedded in practice. Democratizing access to genetic testing and counseling can broaden the reach of patients with RD and increase the diagnostic yield of such indications leading to better medical management as well as expanding research opportunities.